Chongqing Zhifei Biological Products (SHE:300122) obtained clinical trial approval from China's for National Medical Products Administration for its subsidiary Anhui Zhifei Longcom Biopharmaceutical's freeze-dried human rabies vaccine.
The product uses its self-developed human diploid cell line, which induces fewer reactions compared with animal-derived vaccines, according to an after-hours filing on Tuesday with the Shenzhen bourse.
Company shares fell 3% during afternoon trading on Wednesday.